Can Expedited Review Pathways Apply to Innovative Peptide Therapies in China?
Expedited pathways in China are accessible to innovative peptides that demonstrate significant clinical value, requiring strategic navigation of specific regulatory criteria.
HRTioJuly 23, 2025